Avantor (AVTR) investor relations material

Executive summary

• Revival transformation program launched, focusing on go-to-market strategy, operations, portfolio optimization, process simplification, talent/accountability, and VWR brand relaunch.

• Business reorganized into two segments: VWR Distribution and Services (product-agnostic) and Bioscience and Medtech Products (channel-agnostic), enhancing agility and competitiveness.

• 2026 is positioned as a transition year with significant investments to drive sustainable, profitable top-line growth and strengthen competitiveness.

• Emphasis on customer-centricity, brand clarity, operational transparency, and purposeful investment in digital and supply chain upgrades.

• New board members and senior hires to strengthen leadership and accountability.

Financial highlights

• Q4 2025 revenue: $1.66B, down 4% organically; adjusted EBITDA: $252M (15.2% margin); adjusted EPS: $0.22; free cash flow: $117M ($150M excluding transformation expenses).

• Full-year 2025 revenue: $6.552B, down 3% organically; adjusted EBITDA: $1.069B (16.3% margin); adjusted EPS: $0.90; free cash flow: $496M.

• Net loss for 2025: $530M, driven by impairment and transition costs; operating cash flow: $624M.

• $75M in share repurchases in Q4; $300M debt repaid in 2025; adjusted net leverage at 3.2x EBITDA.

• Divestiture of Clinical Services business created a $150M revenue and $50M adjusted EBITDA headwind for FY'25.

Outlook and guidance

• 2026 organic revenue growth expected between -2.5% and -0.5%; reported revenue growth -1.5% to +0.5% with 1% FX tailwind.

• Adjusted EPS guidance for 2026: $0.77–$0.83; free cash flow expected between $500M–$550M, back half-weighted.

• Adjusted EBITDA margin guidance: 14.8% to 15.3%; margin expected to contract by 100–150 bps in 2026 due to mix, investments, and compensation.

• Q1 2026 EPS expected at $0.15–$0.16, with Q1 as the low point for the year.